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Abstract
Background Hypertension is a well-recognized and treatable risk factor for coronary heart disease and is one of the most
common comorbidities associated with obesity. The aim of this study was to characterize the clinical outcome of a cohort of
patients with documented hypertension who underwent laparoscopic gastric bypass.
Methods Ninety-five obese patients with documented hypertension and being treated with antihypertensive medication(s)
underwent laparoscopic gastric bypass. Main outcome measures included length of hypertensive condition, changes in
systolic and diastolic blood pressures, and changes in antihypertensive medication(s) at follow-up.
Results There were 69 (72%) females with a mean preoperative body mass index of 47 kg/m2. The mean duration of
hypertension was 73±70 months. The mean excess body weight loss at 12 months was 66%. The mean systolic blood
pressure significantly decreased from 140±17 mmHg preoperatively to 120±18 mmHg at 12 months (p<0.01). The mean
diastolic blood pressure also significantly decreased from 80±11 mmHg preoperatively to 71±8 mmHg at 12 months (p<0.01).
At 12 months follow-up, 44 (46%) patients had complete resolution of hypertension while 18 (19%) patients had
improvement. Patients with complete resolution had a shorter duration of disease as compared to patients without resolution
(53 vs. 95 months, respectively, p=0.01).
Conclusion Weight loss associated with laparoscopic gastric bypass substantially improves and/or resolves hypertension in
the majority of patients. Improvement of hypertension occurs as early as 1 month postoperatively and is more frequently in
patients with a shorter preoperative duration of disease.
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Background
The prevalence of obesity in the USA is on the rise. It is
estimated that one-third of the adult population in the USA
is obese.1,2 Obesity has been associated with a number of
comorbid conditions such as hypertension, hyperlipidemia,
obstructive sleep apnea, type 2 diabetes, arthritis, and
coronary artery disease.3,4 Of these conditions, hyperten-
sion is the most common comorbidity associated with
obesity. The risk of developing hypertension has been
found to increase with increasing weight class.5 Hyperten-
sion alone is a cardiovascular risk factor but when
combined with obesity, there is a substantially higher
cardiovascular risk.6 A number of studies have shown that
weight reduction is associated with significant improve-
ment or remission of many of the obesity-related comorbid
conditions and can lead to a decrease in the predicted
cardiovascular risk.7–13 Surgery is currently the most
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successful method for sustained weight loss in the morbidly
obese.3,14 There are a number of surgical approaches to
weight loss which include both malabsorptive and/or
restrictive mechanisms. Currently, in the USA, Roux-en-Y
gastric bypass is the most commonly performed bariatric
procedure. The aim of this study was to characterize the
clinical outcomes, specifically with regard to improvement
or resolution of hypertension, of a cohort of morbidly
obese hypertensive patients who underwent laparoscopic
Roux-en-Y gastric bypass.
Materials and Methods
Patient Identification and Selection
We performed a retrospective analysis of our prospectively
collected bariatric database of 95 patients with documented
hypertension who underwent laparoscopic gastric bypass
with a minimum follow-up of 12 months. This group of
patients represented 38% of the cohort of patients who
underwent gastric bypass between 2003 and 2006. All
patients met the 1991 National Institute of Health Consensus
Conference guidelines for bariatric surgery. Our surgical
technique consisted of constructing a 15- to 20-ml transected
gastric pouch with a 150-cm Roux limb. The gastrojejunal
anastomosis was performed in an end-to-side fashion using a
circular stapler. Approval for this retrospective study was
obtained from the University of California Medical Center
Institutional Review Board.
Baseline clinical data including patient characteristics,
length of hypertensive condition, weight, antihypertensive
medication(s) requirement, and blood pressure readings
were obtained at the initial clinic visit. Each patient
underwent three blood pressure measurements and the
average reading was recorded by one of two medical
assistants. All patients with a preexisting diagnosis of
hypertension and currently being treated with antihyperten-
sive medication(s) were included in this review. All patients
were followed postoperatively in an outpatient clinic at
1 week, 1 month, and then at 3 months interval. Medication
adjustments in the postoperative period were made at the
discretion of each patient’s primary care physician. There
was no established protocol for the reduction or discontin-
uation of antihypertensive medication(s). Improvement of
hypertension was defined as a decrease in medication
requirement and a normal blood pressure (systolic pressure
<140 mmHg and diastolic pressure <80 mmHg). Resolution
of hypertension was defined as a normal blood pressure and
discontinuation of all antihypertensive medications. The
Assessment of Obesity-Related Comorbidity (AORC) scale
was used to objectively quantify preoperative and postop-
erative degrees of hypertension.15 The scale of 0 was
defined as not present; a scale of 1 was defined as
borderline/intermittent diagnosis not confirmed; a scale of
2 was defined as controlled by diet and exercise; a scale of
3 was defined as treatment with a single medication; and a
scale of 4 was defined as treatment with multiple
medications.
Statistical Analysis
Continuous variables were expressed as mean±standard
deviation and were analyzed using two-sample t tests.
Categorical variables were analyzed using Fisher’s exact
tests or the Chi-square tests with Yates’ correction when
appropriate. Statistical analysis was performed using SPSS
statistical software, version 12.0 (SPSS Inc., Chicago, IL,
USA). A p value of less than 0.05 was considered
significant.
Results
There were 95 morbidly obese patients with documented
hypertension who underwent laparoscopic gastric bypass
with complete data at 1-year follow-up (Table 1). There
were 26 (28%) males and 69 (72%) females with a mean
age of 47±9 years (range 26–64 years). The mean body
mass index was 47±8 kg/m2. The mean excess body weight
loss was 23% at 1 month, 38% at 3 months, 55% at
6 months, 62% at 9 months, and 66% at 1 year. There were
no in-hospital or 30-day mortalities. The mean duration of
hypertension prior to gastric bypass was 73±70 months.
Preoperatively, all patients were on at least a single
antihypertensive medication; 57 patients (60%) have a
hypertension AORC scale of 3 and 38 patients (40%) have
a hypertension AORC Scale of 4.
Table 1 Characteristics and Outcomes of Hypertensive Morbidly
Obese Patients who Underwent Laparoscopic Gastric Bypass
No. of hypertension patients (N) 95
No. of females (%) 69 (72)
Mean age (years) 47±9
Baseline body mass index (kg/m2) 47±8
Mean duration of disease (months) 73±70
No. of patients with preoperative hypertension
AORC scale=3a (%)
57 (60)
No. of patients with preoperative hypertension
AORC scale=4b (%)
38 (40)
30-day or in-hospital mortality (%) 0 (0)
Mean excess body weight loss at 1 month (%) 23±9
Mean excess body weight loss at 12 months (%) 66±16
AORC scale Assessment of Obesity-Related Comorbidity scale
a Treatment of hypertension with a single medication
b Treatment of hypertension with multiple medications
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There was a significant reduction in mean systolic blood
pressure from 140±17 mmHg preoperatively to 123±
18 mmHg at 1 month and ultimately to 120±18 mmHg at
12 months postoperatively, p<0.01 (Fig. 1). There was also
a significant reduction in the mean diastolic blood pressure
from 80±11 mmHg preoperatively to 75±10 mmHg at
1 month and 71±8 mmHg at 12 months postoperatively, p<
0.01. At 1 month postoperatively, 24 (25%) patients had
complete resolution of hypertension while 34 (36%) had
improvement (Fig. 2). At 12 months postoperatively, 44
(46%) patients had complete resolution while 18 (19%)
patients had improvement of hypertension. Patients with
complete resolution of hypertension at 1 month postoper-
atively had a shorter duration of disease as compared to
those without resolution (38±45 months vs. 87±74 months,
p<0.01). At 12 months postoperatively, the mean duration
of preexisting hypertension was also lower for patients with
resolution of hypertension compared to patients who did
not have resolution, 53±52 months vs. 95±81 months,
respectively, p=0.03 (Table 2). The median percent excess
body weight loss was 57% at 12 months. Of the patients
who achieved excess body weight loss above the median
value, 72% had resolution of hypertension as compared to
19% had resolution for patients who did not achieve the
median weight loss (p<0.01). The 12 months, mean systolic
blood pressure was lower in patients who had resolution of
hypertension when compared to those without resolution,
114±17 mmHg vs. 128±12 mmHg (p=0.02) and the
diastolic blood pressure was also lower in patients who had
resolution of condition, 70±10 mmHg vs. 80±11 mmHg,
respectively, p<0.01. At 12 months, 46% of patients have a
hypertension AORC scale of 0 while 7% and 46% have an
AORC scale of 3 and 4, respectively. Age, gender, race,
preoperative BMI, preoperative blood pressure, preoperative
AORC scale, and preoperative medication requirements were
similar between those with resolution of hypertension and
those without.
Discussion
The main finding of this study is that morbidly obese
patients with hypertension who underwent laparoscopic
gastric bypass had a significant improvement in both
systolic and diastolic blood pressure at 12 months after
surgery and reduction in the need for anti-hypertensive
medications. Improvement in blood pressure was seen as
early as 1 month postoperatively. At 1 month after gastric
bypass, there was 25% complete resolution of hypertension




























*p<0.05, compared to baseline value; Base=Preoperative blood pressure 
Figure 1 Mean change in systolic and diastolic blood pressure in
morbidly obese patients with documented hypertension who under-
went laparoscopic gastric bypass. *p<0.05, compared to baseline
value. Base preoperative blood pressure.
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Figure 2 Improvement or resolution of hypertension in morbidly
obese patients with documented hypertension who underwent laparo-
scopic gastric bypass.
Table 2 Comparisons of Patient with Complete Resolution of






Mean age (years) 46±9 49±8
No of females (%) 33 (75) 34 (67)
No. of Hispanics (%) 8 (18) 6 (12)
No. of African Americans (%) 3 (7) 5 (10)
Mean preoperative no. of
antihypertensive medications
2±1 2±1
Mean duration of hypertensive
disease (months)
55±52* 93±81
Preoperative systolic blood pressure
(mmHg)
136±16 142±17






Diastolic blood pressure at
12 months (mmHg)
70±10* 80±11
*p<0.05, compared to patients without resolution of hypertension
J Gastrointest Surg (2009) 13:793–797 795
complete resolution. Individuals with complete resolution
of hypertension had shorter duration of disease compared to
those without resolution.
Hypertension is the most common comorbidity associ-
ated with obesity. Numerous mechanisms have been
proposed as to how obesity contributes to the development
of hypertension. Some of the proposed mechanisms include
alteration in the renin–angiotensin–aldosterone system,
increased sympathetic nervous system activity, develop-
ment of insulin resistance, hyperleptinemia and leptin
resistance, altered coagulation factors, inflammation, and
endothelial dysfunction.16 Most likely, the mechanism for
hypertension in the obese is multifactorial. The incidence of
hypertension in patients who undergo bariatric surgery
ranges from 40% and up to 70% depending on the definition
for hypertension.10,12,16–19 For example, Fernstrom et al., in
their evaluation of 285 gastric bypass patients, included
patients with stage 1 hypertension (systolic blood pressure
>140 mmHg and diastolic >90 mmHg) without anti-
hypertensive medications and thus found a 57% incidence
of hypertension within their study group.20
The combination of obesity and hypertension places
patients at a higher cardiovascular risk than those patients
without hypertension. This risk can be markedly reduced
after resolution of hypertension following weight loss.19 In
a large population-based study of 197 patients, Batsis et al.
found a significant improvement in hypertension, diabetes,
and dyslipidemia, leading to a decrease in the estimated
10-year risk of cardiovascular events in morbidly obese
patients after gastric bypass.13 In our study, the weight loss
following laparoscopic gastric bypass led to significant
decrease in both systolic and diastolic blood pressure. At
12 months postoperatively, our cohort had a 14% reduction
(by 20 mmHg) in the systolic blood pressure and an 11%
reduction (by 9 mmHg) in the diastolic blood pressure.
Fernstrom et al., in a retrospective review of 347 patients
who underwent either gastric bypass or vertical band gastro-
plasty, reported only a modest reduction in systolic (3 mmHg)
and diastolic (4 mmHg) blood pressure.20 Outcome data from
the Swedish Obese Subjects (SOS) study, which compared
1,157 obese patients who underwent bariatric surgery to
1,031 obese-matched medically treated patients, revealed
marked reductions in both weight and blood pressure in the
surgical group when compared to the medically treated
group.21 The surgically treated group had an improvement of
11 mmHg for systolic blood pressure and 7 mmHg for
diastolic blood pressure. However, by year 8, there was no
difference between the blood pressures of the surgical group
vs. the medically treated group.21 However, in a small subset
of patients who underwent gastric bypass in the SOS study,
weight loss and improvement of hypertension persisted. Other
studies have also reported similar results with continual
improvement/resolution of hypertension after 1 year.20
Multiple studies have shown that weight loss after
gastric bypass will lead to the resolution of multiple
comorbidities. In our study, 46% of patients had complete
resolution of hypertension with 65% of patients showed
improvement or resolution at 12 months. Sugerman et al.
reported a 69% resolution of hypertension in their analysis
of 1,025 gastric bypass patients, which was maintained out
to 5 to 7 years.18 Similarly, Fernstrom et al. found 50%
resolution of hypertension after surgery with no relapse at
12 to 18 months follow-up. In a large meta-analysis that
included 136 studies and 2,115 gastric bypass patients,
Buchwald et al. found that 75% of patients had resolution
and 87% had resolution or improvement of hypertension.3
In a retrospective analysis of 55 veterans who underwent
gastric bypass, Huerta et al. found 89% resolution of
hypertension following the gastric bypass.22 Maggard and
colleagues reviewed 19 studies that reported changes in
hypertension after bariatric surgery and found that resolu-
tion or improvement of hypertension occurred in 25% to
75% of patients while improvement was seen in 95% to
100% of patients following bariatric surgery.14
Our study also showed a relationship between the length
of preexisting hypertension and the likelihood for resolu-
tion of the disease. The mean length of condition was
significantly lower in patients who had complete resolution
of hypertension when compared to those without resolution.
At 1 month after gastric bypass, patients who experienced
resolution of hypertension had a shorter mean length of
hypertension at 38 months compared to 87 months in
patients without resolution. The same was true at 12 months;
patients with resolution of hypertension had a significantly
shorter length of hypertension when compared to those
without resolution. These findings suggest that a length of
preexisting hypertension of less than 4 years may be
predictive for those patients who will not only have
resolution of hypertension following gastric bypass but
those who will resolve sooner. These findings also suggest
that the longer hypertension persists, the more functional and
structural changes accompany the disease and the more
difficult for the disease to resolve.23,24 This was previously
proposed by Sugerman et al.18 Given this finding, perhaps
bariatric surgery should be offered much sooner to
morbidly obese patients with hypertension, as length of
preexisting condition is an important factor predicting its
resolution.
Conclusion
In conclusion, weight loss associated with laparoscopic
gastric bypass significantly improves systolic and diastolic
blood pressure and is effective in leading to discontinuation
or a marked reduction of hypertensive medication
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requirements in a large proportion of morbidly obese
hypertensive patients. These findings occur as early as
1 month postoperatively and seem to be associated with
the duration of preexisting disease. Moreover, patients
with a length of preexisting hypertension of less than
4 years are more likely to have resolution of hyperten-
sion. This suggests that perhaps patients with morbid
obesity and hypertension should be offered surgical
weight loss earlier in their disease process.
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